Suppliers and packagers for DEFLAZACORT

DEFLAZACORT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sun Pharm Inds Inc	DEFLAZACORT	deflazacort	SUSPENSION;ORAL	219930	ANDA	Sun Pharmaceutical Industries, Inc.	57664-993-01	13 mL in 1 BOTTLE (57664-993-01)	2026-02-02
Tris Pharma Inc	DEFLAZACORT	deflazacort	SUSPENSION;ORAL	217813	ANDA	Cranbury Pharmaceuticals, LLC	27808-249-01	13 mL in 1 BOTTLE (27808-249-01)	2024-05-01
Zydus Lifesciences	DEFLAZACORT	deflazacort	SUSPENSION;ORAL	220042	ANDA	Zydus Pharmaceuticals (USA) Inc.	70710-2007-3	1 BOTTLE in 1 CARTON (70710-2007-3) / 13 mL in 1 BOTTLE	2025-10-23
Zydus Lifesciences	DEFLAZACORT	deflazacort	SUSPENSION;ORAL	220042	ANDA	Zydus Pharmaceuticals (USA) Inc.	70710-2131-3	1 BOTTLE in 1 CARTON (70710-2131-3) / 13 mL in 1 BOTTLE	2025-11-20
Zydus Lifesciences	DEFLAZACORT	deflazacort	SUSPENSION;ORAL	220042	ANDA	Doppel Farmaceutici S.r.l.	81806-200-73	1 BOTTLE in 1 CARTON (81806-200-73) / 13 mL in 1 BOTTLE	2025-10-23
Amneal	DEFLAZACORT	deflazacort	TABLET;ORAL	217173	ANDA	Amneal Pharmaceuticals NY LLC	60219-2282-1	1 BOTTLE in 1 CARTON (60219-2282-1) / 100 TABLET in 1 BOTTLE	2025-12-12

Deflazacort Pharmaceutical Supply Chain Analysis

Last updated: February 19, 2026

This report details the global supply chain for deflazacort, a corticosteroid used in the treatment of Duchenne muscular dystrophy and other inflammatory conditions. It identifies key manufacturers, active pharmaceutical ingredient (API) suppliers, and highlights regulatory landscapes impacting production and distribution.

Who are the Primary Manufacturers of Deflazacort?

The global market for deflazacort is served by a concentrated group of pharmaceutical manufacturers. These companies are responsible for both the formulation of the finished drug product and, in some cases, the synthesis of the active pharmaceutical ingredient (API). Key players include:

• Santhera Pharmaceuticals AG: A Swiss biopharmaceutical company holding significant market presence. Santhera's brand name for deflazacort is Emflaza.
• Takeda Pharmaceutical Company Limited: A global pharmaceutical giant with a strong portfolio in rare diseases. Takeda acquired the rights to Emflaza in the United States from Marathon Pharmaceuticals.
• Ipsen S.A.: A French biopharmaceutical group that has also been involved in the marketing and distribution of deflazacort in various regions.
• Generic Manufacturers: A growing number of generic pharmaceutical companies are entering the market, particularly in regions with less stringent regulatory oversight or following patent expiries. These include companies such as Azurity Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd., among others.

The market share distribution is dynamic, influenced by patent protection, regional approvals, and the expansion of generic alternatives. Santhera and Takeda hold substantial positions due to their established brands and market access strategies.

What are the Key Active Pharmaceutical Ingredient (API) Suppliers?

The synthesis of deflazacort API is a complex chemical process typically undertaken by specialized API manufacturers. These suppliers are critical nodes in the supply chain, providing the bulk drug substance to formulators. Identifying all definitive API suppliers is challenging due to proprietary contractual agreements and the confidential nature of pharmaceutical sourcing. However, the landscape includes:

• Global Contract Manufacturing Organizations (CMOs): A significant portion of API manufacturing is outsourced to CMOs with expertise in steroid synthesis. These often include companies based in India and China, known for their cost-effectiveness and large-scale production capabilities.
• In-house Manufacturing by Brand Manufacturers: Some brand manufacturers, such as those with established long-term manufacturing capabilities, may produce their own API. However, outsourcing to specialized API producers is a common strategy to manage costs and production capacity.
• Specialized Chemical Synthesis Companies: Certain chemical companies focus on the production of complex organic molecules, including steroid derivatives, and serve the pharmaceutical industry.

Key considerations for API sourcing include Good Manufacturing Practice (GMP) compliance, quality control, supply chain reliability, and cost. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) scrutinize API manufacturing sites as part of drug approval processes.

What are the Regulatory Requirements for Deflazacort Manufacturing?

The manufacturing of deflazacort, both API and finished drug product, is subject to stringent regulatory oversight globally. These regulations ensure product quality, safety, and efficacy.

• Good Manufacturing Practices (GMP): All manufacturing facilities must adhere to GMP standards as defined by regulatory authorities like the FDA (21 CFR Parts 210 & 211) and the EMA. This encompasses all aspects of production, including personnel, premises, equipment, documentation, and quality control.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers typically file DMFs (in the US) or ASMFs (in the EU) with regulatory agencies. These confidential documents contain detailed information about the API manufacturing process, facilities, and quality controls, which are reviewed by authorities during the evaluation of finished drug product applications.
• Marketing Authorization Applications (MAAs) / New Drug Applications (NDAs): Pharmaceutical companies seeking to market deflazacort must submit comprehensive applications demonstrating the quality, safety, and efficacy of their product. This includes detailed information on the API source, manufacturing processes, and stability data.
• Inspections: Regulatory agencies conduct routine inspections of manufacturing facilities to ensure ongoing compliance with GMP and other relevant regulations.
• Import/Export Controls: International shipments of both API and finished drug products are subject to import and export regulations, including customs declarations and adherence to country-specific drug laws.
• Pharmacopoeial Standards: Deflazacort API and finished products must comply with the standards set forth in national pharmacopoeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.).

The regulatory environment for deflazacort is influenced by the specific indications for which it is approved. For instance, its approval for Duchenne muscular dystrophy in certain markets may involve specific post-marketing commitments or data collection requirements.

What are the Key Market Dynamics and Trends?

The market for deflazacort is shaped by several key factors:

• Orphan Drug Designation: In many jurisdictions, deflazacort for specific rare disease indications, like Duchenne muscular dystrophy, has received orphan drug designation. This designation provides market exclusivity for a defined period (e.g., 7 years in the US, 10 years in the EU) for the approved indication, encouraging development and investment.
• Patent Expiries and Generic Competition: As patents for branded deflazacort products expire, the market becomes more accessible to generic manufacturers. This leads to increased competition and typically a reduction in drug prices. The timing of patent expiry varies by region and specific patent.
• Geographic Expansion: Manufacturers actively seek regulatory approval and market access for deflazacort in new territories. This involves navigating diverse regulatory pathways and understanding local market access dynamics.
• Therapeutic Advancements: Ongoing research into the efficacy and safety of deflazacort for various inflammatory and autoimmune conditions, as well as its potential use in combination therapies, could influence future demand.
• Supply Chain Resilience: Recent global events have highlighted the importance of robust and resilient pharmaceutical supply chains. Companies are increasingly focused on diversifying their supplier base, managing geopolitical risks, and ensuring continuity of supply.
• Pricing and Reimbursement: The pricing of deflazacort is a critical factor, particularly for orphan indications where treatment costs can be substantial. Reimbursement policies by national health systems and private insurers significantly impact market penetration.

What are the Primary Risks and Challenges in the Supply Chain?

The deflazacort supply chain faces several inherent risks and challenges:

• API Sourcing Reliability: Dependence on a limited number of API suppliers, particularly those concentrated in specific geographic regions, creates vulnerability to disruptions. Geopolitical instability, natural disasters, or regulatory actions against an API manufacturer can impact supply.
• Quality Control and Compliance: Maintaining consistent API and finished product quality across all manufacturing sites is paramount. Deviations from GMP or adverse findings during regulatory inspections can lead to production halts and product recalls.
• Intellectual Property Disputes: Patent litigation and challenges to patent validity can create uncertainty regarding market exclusivity and the potential for earlier generic entry, impacting investment and pricing strategies.
• Regulatory Hurdles: Navigating complex and evolving regulatory requirements in different countries can lead to delays in market entry or approval for product variations. Changes in regulatory policy or the emergence of new safety concerns can also pose challenges.
• Price Pressures: The introduction of generic competitors and pressure from payers to control healthcare costs can lead to significant price erosion, impacting the profitability of both branded and generic products.
• Logistics and Distribution: Ensuring the secure and timely distribution of deflazacort, often requiring specific storage conditions (e.g., temperature control), across global markets presents logistical complexities.

Key Takeaways

• The deflazacort market is dominated by a few key brand manufacturers, but a growing generic presence is increasing competition.
• API sourcing relies on specialized manufacturers, often located in Asia, emphasizing the need for robust quality control and supply chain diversification.
• Stringent global regulatory frameworks, including GMP and detailed drug master files, govern all aspects of deflazacort production.
• Market dynamics are significantly influenced by orphan drug designations, patent expiries, and evolving reimbursement policies.
• Key risks include API supply disruptions, quality control failures, intellectual property disputes, and intense price pressures.

Frequently Asked Questions

1. What are the primary therapeutic indications for deflazacort? Deflazacort is primarily indicated for the treatment of Duchenne muscular dystrophy (DMD) in eligible patients. It is also used for other inflammatory and autoimmune conditions where corticosteroid therapy is indicated, such as juvenile idiopathic arthritis, nephrotic syndrome, and certain allergic and dermatologic disorders.

2. How does deflazacort differ from other corticosteroids? Deflazacort is a glucocorticoid with a unique structural modification that results in a lower incidence of certain corticosteroid-related side effects, particularly bone demineralization and cataracts, compared to some other corticosteroids at equipotent doses. It is considered to have a more favorable benefit-risk profile in specific patient populations, especially those requiring long-term treatment.

3. What is the typical shelf life and storage requirement for deflazacort products? The typical shelf life for deflazacort tablets and oral suspensions is generally between 24 to 36 months when stored at controlled room temperature (e.g., 20°C to 25°C or 68°F to 77°F). Specific storage conditions may vary slightly by product formulation and manufacturer, and it is crucial to refer to the product's official labeling for precise instructions. It should be protected from moisture and excessive heat.

4. Which regulatory bodies have approved deflazacort for Duchenne muscular dystrophy? Deflazacort has received approval for Duchenne muscular dystrophy from major regulatory bodies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Other national health authorities globally have also granted approvals for this indication.

5. Are there any significant manufacturing barriers or entry costs for new deflazacort API producers? Yes, significant barriers exist for new deflazacort API producers. These include the substantial capital investment required for GMP-compliant manufacturing facilities, specialized expertise in steroid synthesis chemistry, rigorous process validation, and the complex and costly process of preparing and filing Drug Master Files (DMFs) or Active Substance Master Files (ASMFs) with regulatory agencies. Obtaining regulatory approval and undergoing routine inspections represent significant ongoing compliance costs.

Citations

[1] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 210 - Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. Retrieved from [FDA Website] [2] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals. Retrieved from [FDA Website] [3] European Medicines Agency. (n.d.). Good Manufacturing Practice. Retrieved from [EMA Website] [4] Santhera Pharmaceuticals AG. (2023). Annual Report 2022. Retrieved from [Santhera Investor Relations] [5] Takeda Pharmaceutical Company Limited. (2023). Annual Report 2022. Retrieved from [Takeda Investor Relations] [6] Ipsen S.A. (2023). Annual Report 2022. Retrieved from [Ipsen Investor Relations] [7] U.S. Food and Drug Administration. (n.d.). Orphan Drug Designation. Retrieved from [FDA Website] [8] European Medicines Agency. (n.d.). Orphan medicinal products. Retrieved from [EMA Website] [9] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from [USP Website] [10] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from [EDQM Website]